Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$167.6MCash, Jun 2026
23moCash Runway (est.)
+5%Share Count, 1 Year
Follow FHTX by emailGet an email when FHTX pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about FHTX, unsubscribe in one click. Privacy
📣 What FHTX Says Is Next
in 2027 · “IND targeted in 2027 , with a focus in MM and DLBCL.”
Company press release, Aug 6, 2026 · SEC filing
in 2027 · “We are targeting an IND in 2027 for this asset, underscoring the breadth of our platform and demonstrating its potential across multiple therapeutic areas.”
Company press release, Aug 6, 2026 · SEC filing
in 2026 · “IND-enabling studies anticipated in 2026 with expected IND in 2027.”
Company press release, May 7, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
💰 Cash Runway & Dilution Risk
FHTX reported $167.6M in cash and short-term investments (as of Jun 30, 2026) and used about $21.7M/quarter in operations, an estimated runway of 23.1 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:33 · Moderate
Cash runway 23 months +8
ATM program on file since Mar 2025 +15
Shelf registration (S-3, Jan 2025) +10
Recent financing filings on SEC EDGAR:
Jan 12, 2026 · Registered direct / best-efforts offering · 424B5
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for FHTX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.